reports
JDE Peet’s share buyback periodic update August 25, 2025
JDE Peet’s share buyback periodic update August 25, 2025 PRESS RELEASE Amsterdam, August 25, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 230,025 shares in the period from August 18, 2025 up to and including August 22, 2025. The shares were repurchased at an average price of EUR 26.60 per share for a total consideration of EUR 6.1 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 5,477,094 ordinary s...
- Robert Jan Vos
- Michiel Declercq
JDE Peets Keurig Dr. Pepper makes € 31.85ps all cash offer for JDEP
This morning, Keurig Dr Pepper (KDP) and JDE Peet's announced that they have entered into a definitive agreement under which KDP will acquire JDE Peet's in an all cash offer. Subsequently, KDP will separate its refreshment beverage (Beverage Co) and coffee business (Global Coffee Co) into two independent companies. Under the terms of the transaction, KDP will pay JDE Peet's shareholders € 31.85ps, representing a total equity consideration of € 15.7bn. JDE Peet's will also pay the previously decl...
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
argenx Vyvgart meets primary endpoint in snMG paving path for label ex...
argenx announced positive topline data from the pivotal ADAPT SERON study of Vyvgart in AchR-Ab seronegative gMG (snMG), showing a statistically significant improvement vs. placebo (p-value=0.0068) on the primary endpoint of MG-ADL. The positive topline results do not come as a surprise, and confirm previously reported pooled analysis showing improvements in the MG-ADL score in this gMG sub-population. The company plans to file for label expansion with the FDA, and estimates the commercial oppor...
Keurig Dr Pepper to Acquire JDE Peet’s and Subsequently Separate into ...
Keurig Dr Pepper to Acquire JDE Peet’s and Subsequently Separate into Two Independent Companies – a Leading Refreshment Beverage Player and a Global Coffee Champion Acquisition to create global coffee leader serving 100+ countries with an unparalleled brand portfolio across all coffee segments, channels and price points Subsequent separation to establish a fast-growing and scaled North American refreshment beverage player and the world’s #1 pure-play coffee company Each company will be positioned to win with focused strategies and attractive growth models, powered by iconic brand portf...
argenx Announces Positive Topline Results from ADAPT SERON Study of VY...
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to be submitted to U.S. Food and Drug Administration (FDA) by end of 2025 August 25, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving t...
Argen X SE: 1 director
A director at Argen X SE sold 426 shares at 547.910EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by...
JDE Peet’s share buyback periodic update August 18, 2025
JDE Peet’s share buyback periodic update August 18, 2025 PRESS RELEASEAmsterdam, August 18, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 247,873 shares in the period from August 11, 2025 up to and including August 15, 2025. The shares were repurchased at an average price of EUR 26.03 per share for a total consideration of EUR 6.5 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 5,247,069 ordinary shar...
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of My...
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
JDE Peet’s share buyback periodic update August 11, 2025
JDE Peet’s share buyback periodic update August 11, 2025 PRESS RELEASEAmsterdam, August 11, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 167,402 shares in the period from August 4, 2025 up to and including August 8, 2025. The shares were repurchased at an average price of EUR 25.77 per share for a total consideration of EUR 4.3 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 4,999,196 ordinary shares...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Wim Lewi
- Jacob Mekhael
argenx Upping our FY25 estimates after a solid 2Q25 beat
Following argenx' 2Q25 results with Vyvgart sales coming in at $ 949m, and beating CSS by 10%, we update our model, upping our Vyvgart sales estimates for FY25 to $ 3.98b (from $ 3.61b, Visible Alpha CSS: $ 3.97b). We factor in potential competition from IMAAVY (J&J), though we continue to see Vyvgart as the better product, and model approx. 12% q/q growth for 3Q25 and 4Q25. Additionally, we slightly tweak our CIDP numbers bringing us to higher peak sales ($ 4.22b vs. $ 3.76b). All in all, our t...
- Guy Sips
- Kristof Samoy
- Michiel Declercq
- Michiel Declercq
JDE Peets 1H25 results confirm coffee's positioning as a staple good
Last week Wednesday, JDE Peet's surprised with a strong set of 1H25 results, with the vol/mix increasing 1.0% despite a significant price increase of 21.5%. While the vol/mix effect was positively impacted by around 2-3% from customers pre-buying ahead of further anticipated price hikes, the underlying price elasticity remains resilient. This reconfirms coffee's positioning as a staple good. While price elasticity is expected to slightly deteriorate in 2H25, it should remain at healthy levels. A...
JDE Peet’s share buyback periodic update August 4, 2025
JDE Peet’s share buyback periodic update August 4, 2025 PRESS RELEASEAmsterdam, August 4, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 102,859 shares in the period from July 28, 2025 up to and including August 1, 2025. The shares were repurchased at an average price of EUR 24.10 per share for a total consideration of EUR 2.5 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 4,831,794 ordinary shares fo...
- Jacob Mekhael
argenx 1H25 conference call feedback
argenx reported 1H25 results today, with Vyvgart sales showing a solid CSS beat. In this note you can find our main takeaways from the conference call. ARGX-119 phase 3 in CMS - argenx emphasized that they currently have 3 assets in phase 3 development with the advancement of ARGX-119 to phase 3 in Congenital Myasthenic Syndrome (CMS). ARGX-119 targets MuSK in the neuromuscular junction and is advanced in CMS, an ultra-rare disease. This allows for a small trial with dense monitoring of patients...
- Louis Boujard
- CFA
- Philippe Ourpatian
- Thomas Zlowodzki
V1S ARKEMA
LHN HOLCIM AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
AC ACCOR SA
VIE VEOLIA ENVIRONNEMENT SA
IPN IPSEN SA
RR. ROLLS-ROYCE HOLDINGS PLC
EDP EDP-ENERGIAS DE PORTUGAL SA
DG VINCI SA
UBSN UBS GROUP AG
MT ARCELORMITTAL SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
RNO RENAULT SA
LI KLEPIERRE SA
RI PERNOD RICARD SA
RMS HERMES INTERNATIONAL SCA
DAI DAIMLER AG
EN BOUYGUES SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
OMV OMV AG
KOMB KOMERCNI BANKA A.S.
ISP INTESA SANPAOLO S.P.A.
SAN SANOFI
SAF SAFRAN S.A.
HEI HEIDELBERGCEMENT AG
AIR AIRBUS SE
VER VERBUND AG CLASS A
CAP CAPGEMINI SE
UCB UCB S.A.
01913 PRADA S.P.A.
BA. BAE SYSTEMS PLC
NEM NEMETSCHEK SE
ARCAD ARCADIS NV
EDW EDP RENOVAVEIS SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
PRY PRYSMIAN S.P.A.
ANDR ANDRITZ AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
ABI BANCO SANTANDER S.A.
RIO ANHEUSER-BUSCH INBEV SA/NV
LDO RIO TINTO PLC
SNP LEONARDO SPA
ARGX PETROM S.A.
SHL ARGEN-X SE
ULA SIEMENS HEALTHINEERS AG
KBX UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
NEXI KNORR-BREMSE AG
FDJ NEXI S.P.A.
SHEL LA FRANCAISE DES JEUX SA
P911 SHELL PLC
DSFIR DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ARM KONINKLIJKE DSM N.V.
TEN ARM HOLDINGS PLC
SYENS TENARIS S.A.
AAL SYENSQO
ANGLO AMERICAN PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.